Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Buzz around Exploratory INDs

This article was originally published in Start Up

Executive Summary

The impact of FDA's Final Guidance on the use of Exploratory IND Studies could be profound for firms ranging from start-ups anticipating their first human drug tests to Big Pharmas with thousands of leads to manage and prioritize. Some service organizations may also benefit from the new regs, which may prompt an early clinical assessment of increasing numbers of compounds.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC091218

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel